Altimmune, Inc. (ALT) - A hidden GEM?
Who: Altimmune, Inc. (ALT)
WHAT: Phase 1 met primary endpoint, they will be presenting data on April 12, 2019.
WHAT: HepTcell is an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (“HBV”).It is designed to driveCD4+ and CD8+ T-cell responses against all HBV genotypes in patients of all ethnic backgrounds. Stimulating T-cell responses in chronically infected HBVpatients has been challenging because chronic infection with HBV strongly diminishes T-cell immunity directed against the virus. HepTcell focuses the immune system on discrete highly conserved regions of the HBV proteome. We believe our approach allows HepTcell to break immune tolerance by activating T-cells against critical viral sequences with decreased probability of immune escape due to viral mutation. HepTcell is based on our synthetic peptide technology platform and is given by intramuscular injection. In 2018 we completed a Phase 1 trial in the United Kingdom and South Korea inpatients with chronic HBV. The HepTcell Phase 1 trial was a double-blinded, placebo-controlled, randomized, dose-escalation study that enrolled 61 subjects with chronic HBV who were HBeAg-negative and well-controlled on licensed antivirals. A total of 41 patients received one of two dose levels of HepTcell,with and without IC31TM, a depot-forming TLR9 adjuvant developed by Valneva SE, while 20 control patients received either placebo or IC31 alone. Patients received three injections each 28 days apart and were followed for six months after the final dose. All dose combinations showed excellent tolerability and met the primary endpoint of safety. In the two adjuvanted HepTcell arms, T-cell responses against HBV markedly increased over baseline compared to placebo. Altimmune plans to advance HepTcell into Phase 2 development.
A couple things to note about $ALT:
|Beta (3Y Monthly)||2.47|
|52-Week Change 3||-89.88%|
|S&P500 52-Week Change 3||9.67%|
|52 Week High 3||36.2500|
|52 Week Low 3||1.7000|
|50-Day Moving Average 3||2.9434|
|200-Day Moving Average 3||3.9985|
As you can see on the 1 day 30 minute chart for 04/02/2019:
Indicators are telling us that there is a sell off coming, and shorts are also increasing on this stock. $ALT is already trading below VWAP + EMA - on watch!
Technical chart claims that Altimmune, Inc. (ALT) would settle between $2.90/share to $3.31/share level. However, if the stock price goes below the $2.90 mark, then the market for Altimmune, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $2.82 for its downside target. The stock is currently in the danger zone of MACD, with the indicator reading -29.762 on the 1D 30M chart. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.